Lung Cancer | Specialty

Personalizing Lung Cancer Treatment Reduces Toxicity and Improves Cure Rates

May 8th 2025

New lung cancer treatment options have emerged, and several groups are exploring treatment strategies that omit chemotherapy for locally advanced NSCLC.

Redefining Translational Research and China’s Impact on US Drug Development

May 7th 2025

In a 3-part series, Evan S. Wu, MD, PhD, will explore key issues surrounding the translatability of Chinese drug development data to a US population.

Giants of Cancer Care® Announces the 13th Annual Class of Inductees

May 7th 2025

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.

Navigating the Evolving Treatment Landscape for Early-Stage NSCLC: Personalizing Care Through Biomarker-Guided Strategies and Multidisciplinary Approaches

May 7th 2025

Panelists discuss how the latest efficacy and safety data from AEGEAN, CheckMate 816, CheckMate 77T, and KEYNOTE-671, along with recent approvals in early-stage non–small cell lung cancer (NSCLC) treatment, are shaping optimized treatment approaches and influencing clinical practice.

Enhancing Early-Stage NSCLC Diagnosis: Leveraging Pathology and Imaging for Accurate Staging

May 7th 2025

Panelists discuss how a multidisciplinary team—including oncologists, thoracic surgeons, radiologists, and pathologists—collaborates to streamline the diagnostic process for patients with resectable non–small cell lung cancer (NSCLC), ensuring timely evaluation, accurate staging, and personalized treatment planning.

Dr Shum on the Evolving Treatment Paradigm for EGFR+ NSCLC

May 6th 2025

Obrixtamig Could Broaden the Reach of DLL3/CD3-Targeted BiTEs in Small Cell Lung and Other Neuroendocrine Cancers

May 5th 2025

The DLL3- and CD3-targeted BiTE obrixtamig is being evaluated in patients with SCLC and other neuroendocrine cancers in the phase 2 DAREON-5 study.

Targeted Therapy Developments and Screening Updates Broaden the NSCLC Treatment Paradigm

May 5th 2025

Alexis Chidi, MD, PhD, MSPH, emphasizes the importance of having more available targeted therapies and explains NSCLC screening eligibility criteria.

Ventana TROP2 (EPR20043) RxDx Device Receives FDA Breakthrough Device Designation for Dato-DXd Selection in NSCLC

May 5th 2025

The AI-driven companion diagnostic device Ventana TROP2 (EPR20043) RxDx has received FDA breakthrough device designation in NSCLC.

Less Is More With Advanced Surgical Approaches in Early-Stage NSCLC

May 2nd 2025

Alexis Chidi, MD, PhD, MSPH, details the evolution of surgical approaches in early-stage lung cancer, including wedge resections and segmentectomies.

Adjuvant Aumolertinib Boosts DFS in Stage II-IIIB, EGFR-Mutated NSCLC

April 30th 2025

Adjuvant aumolertinib improved disease-free survival in complete resected stage II to IIIB non–small cell lung cancer harboring EGFR mutations.

Adagrasib Yields Early Efficacy in STK11- and KRAS G12C–Mutant NSCLC

April 30th 2025

First-line adagrasib monotherapy demonstrated preliminary efficacy and tolerability in patients with SK11- and KRAS G12C–mutant NSCLC.

Lung Cancer Experts Highlight the Significance and Limitations of ADCs

April 30th 2025

Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

A Focus on the Role of Patient Navigators in the Diagnosis and Management of Early-Stage NSCLC

April 30th 2025

Panelists discuss how a multidisciplinary team (MDT) approach to resectable non–small cell lung cancer (NSCLC) involves an initial diagnostic workup with imaging (CT, PET-CT), histologic confirmation via biopsy, staging with mediastinal assessment (endobronchial ultrasound or mediastinoscopy), and timely molecular testing (eg, EGFR, ALK, PD-L1) integrated early in the process to guide perioperative treatment decisions.

Expert Insights and Best Practices in Diagnosing Resectable Early-Stage NSCLC

April 30th 2025

Panelists discuss how a multidisciplinary approach enhances the early diagnosis of non–small cell lung cancer (NSCLC) by integrating insights from oncology, radiology, pathology, and surgery.

Dr Loong on the Efficacy of D3S-001 in KRAS G12C Inhibitor–Resistant NSCLC

April 30th 2025

Herbert H F Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, discusses the efficacy of D3S-001 in pretreated NSCLC.

Early ctDNA Clearance Is Associated With Response to Daraxonrasib in RAS-Mutant NSCLC

April 28th 2025

Early complete clearance of ctDNA was linked with clinical responses to daraxonrasib in RAS-mutant advanced non–small cell lung cancer.

Tiragolumab Plus Atezolizumab Fails to Meet Survival End Points in Previously-Untreated, PD-L1–High NSCLC

April 28th 2025

First-line tiragolumab plus atezolizumab did not improve PFS and OS vs atezolizumab alone in PD-L1–high, unresectable or metastatic NSCLC.

Ivonescimab Wins NMPA Approval in China for First-Line, PD-L1+ Advanced NSCLC

April 28th 2025

China’s NMPA approved ivonescimab for the first-line treatment of PD-L1–positive advanced non–small cell lung cancer.

Presenting the Treatment Options in EGFR-Mutant NSCLC: Weighing the Data and Incorporating the Patient Perspective

April 28th 2025

Panelists discuss how conversations with patients about treatment options have become more complex and nuanced, requiring thorough explanation of efficacy data and adverse effects while adapting to each patient’s level of understanding and involvement.